News 02.21

Sébastien Iva, new CEO of Fabentech


Sébastien Iva is the new Chief Executive Officer of Fabentech, a Lyon-based biotech created in 2009 and specialised in the development and production of polyclonal antibodies intended for the treatment of emerging infectious diseases and the development of biodefence solutions. His mission is to ensure its development and transformation, with the stated objective of becoming a key player in the field of polyclonal antibodies. He took over from Bertrand Lépine, founder of Fabentech, who now becomes a member of the Supervisory Council.

Graduate of the ESC higher school of commerce – with further training at the HEC and INSEAD business schools -, Sébastien Iva has close to 25 years of professional experience in the health sector.

He started his career in marketing and sales in 1996 at the Sanofi head office, before working in Asia for several years. In 1999, he joined Stallergenes-Greer, a company specialising in allergen immunotherapy – a market leader and rapid international expansion – as a member of the senior executive  team. He thus strongly contributed to the international development of activities.

After 12 years in various senior management roles at Stallergenes-Greer, Sébastien successfully led the restructuration of International Operations in Thuasne, a major player in the field of medical devices. More recently, he has been COO (Chief Operating Officer) of a Swiss start-up specialised in the diagnosis of neurological diseases. His experience in start-ups, and within international groups, gives him the skills to transform Fab’entech and accelerate projects initiated over the last few years.

I am very pleased to be taking up the chairmanship of Fab’entech at a pivotal point in its history. We are tackling several big projects at once, notably the development of a COVID-19 treatment and the creation of a new industrial site in the Lyon region to manufacture rapidly and at large-scale, in France. We also have ambitious programmes in the development of biodefence solutions in collaboration with the General Directorate of Armaments (DGA). We are currently finalising the first portion of a new fundraising round to accelerate our ongoing programmes. These dimension-setting projects will help to establish Fab’entech as a major player in the treatment of emerging infectious diseases and medical countermeasure solutions

concludes Sébastien Iva.